Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
Status:
Completed
Trial end date:
2019-09-24
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different
intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg
aflibercept every 8 weeks after 5 initial monthly injections for approximately 1 year or more
(according to the EU label for the first year of treatment)